| ORIGINAL ARTICLE |
|
| Year : 2015 | Volume
: 4
| Issue : 1 | Page : 257 |
|
|
Pulsed dye laser and topical timolol gel versus Pulse dye laser in treatment of infantile hemangioma: A double-blind randomized controlled trial
Ali Asilian1, Fatemeh Mokhtari2, Atefeh Sadat Kamali3, Bahareh Abtahi-Naeini2, Mohammad Ali Nilforoushzadeh4, Shayan Mostafaie5
1 Department of Dermatology; Skin Diseases and Leishmaniasis Research Center, Tehran University of Medical Sciences, Tehran; Isfahan University of Medical Sciences; Isfahan, Iran
2 Department of Dermatology, Tehran University of Medical Sciences, Tehran; Isfahan University of Medical Sciences; Isfahan, Iran
3 Department of Dermatology; Isfahan University of Medical Sciences; School of Medicine, Tehran University of Medical Sciences; Tehran, Iran
4 Skin Diseases and Leishmaniasis Research Center; Skin and Stem Cell Research Center; Tehran University of Medical Sciences, Tehran, Iran
5 Isfahan University of Medical Sciences; Department of Epidemiology and Biostatistics, School of Public Health, Isfahan, Iran
Correspondence Address:
Atefeh Sadat Kamali
Department of Dermatology, Isfahan University of Medical Sciences, Al-Zahra Hospital, Soffeh Blvd, Isfahan
Iran
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2277-9175.170682
|
|
|
Background: Infantile hemangioma (IH) is the most common tumor during infancy that usually appears as macular and gradually becomes a plaque or tumor. Approximately, 20% of all IH cases results in adverse effects and the Pulsed dye laser (PDL) 585 nm is a vascular laser leading to selective the micro vascular damage. Results of studies on non-selective B-blockers (e.g., timolol) indicate their effectiveness in preventing hemangioma growth. The aim of this study is a comparison of PDL plus timolol and PDL in the treatment of IH.
Materials and Methods: This double-blind study was carried out on 30 infants (1-12 months old) and the patients were divided into two groups. Group A was treated with the four sessions PDL and the timolol gel 0.05% and Group B with PDL.
Results: There were no differences in the mean age of patients for the diagnosis of hemangioma (Group A: 32.69 ± 24.64 days, Group B: 25.69 ± 21.16 days, P = 0.39) and the mean age at the start of the treatment (Group A: 148.125 ± 85.88 days, Group B: 146.25 ± 60.87 days, P = 0.94). There were a statistical difference in the mean of lesion size reduction (Group A: 17.62 ± 6.97 cm and Group B: 12 ± 5.71 cm, P = 0.018), mean percentage change in size mean (Group A: 71079 ± 23.41% and Group B: 54.59 ± 25.46%, P = 0.050) visual analog scale (Group A: 7.19 ± 1.51, Group B: 5.62 ± 1.78, P = 0.012) after treatment. There was no correlation between the time of beginning the treatment and the results (P = 0.857).
Conclusions: Application of timolol with PDL is accompanied by the highest efficacy, cost benefits and the short time of treatment. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
